Odyssey Therapeutics, Inc. (ODTX)

Odyssey Therapeutics was planning to go public, but the IPO was withdrawn on Jun 9, 2025.

Stock Price: Pending

IPO price not available yet

Odyssey Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	3	1.04	-
Gross Profit	3	1.04	-
Selling, General & Admin	-	22.2	21.02
Research & Development	-	112.28	101.76
Other Operating Expenses	0	0.3	5.13
Operating Expenses	-	134.77	127.9
Operating Income	-130.71	-133.74	-127.9
Interest Expense / Income	-9.22	-8.46	-3.63
Other Expense / Income	0.24	0.21	0.05
Pretax Income	-126.89	-130.47	-124.32
Income Tax	0.52	0.45	0.35
Net Income	-122.25	-125.94	-124.67
Net Income Common	-127.41	-130.92	-124.67
Free Cash Flow	-112.2	-117.78	-112.87
Gross Margin	100.00%	100.00%	-
Operating Margin	-4351.10%	-12896.43%	-
Profit Margin	-4241.18%	-12624.88%	-
Free Cash Flow Margin	-3734.95%	-11358.15%	-
EBITDA	-125.82	-129.04	-125.19
EBITDA Margin	-4188.25%	-12443.59%	-
Depreciation & Amortization	5.13	4.91	2.76
EBIT	-130.95	-133.95	-127.95
EBIT Margin	-4359.09%	-12916.88%	-

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).